Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)
- 1 March 2007
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 99 (5) , 632-635
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin InteractionJournal of the American Geriatrics Society, 2006
- Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled TrialJAMA, 2001
- Rationale and Design of the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study11See Appendix Afor the list of participants in the MIRACL study. That Evaluates Atorvastatin in Unstable Angina Pectoris and in Non–Q-Wave Acute Myocardial InfarctionThe American Journal of Cardiology, 1998